LU; Hsieng Sen
Patent Applications and Registrations
Patent applications and USPTO patent grants for LU; Hsieng Sen.The latest application filed is for "human cgrp receptor binding proteins".
- LU; Hsieng Sen - Westlake Village CA
- LU; Hsieng Sen - Thousand Oaks CA
| Patent | Date |
|---|---|
| Human Cgrp Receptor Binding Proteins App 20210179722 - BOONE; Thomas C. ; et al. | 2021-06-17 |
| Human Cgrp Receptor Binding Proteins App 20210179723 - BOONE; Thomas C. ; et al. | 2021-06-17 |
| Dkk1 Antibodies And Methods Of Use App 20210040189 - RICHARDS; William Gleason ; et al. | 2021-02-11 |
| DKK1 antibodies and methods of use Grant 10,800,839 - Richards , et al. October 13, 2 | 2020-10-13 |
| Human Cgrp Receptor Binding Proteins App 20180142029 - BOONE; Thomas C. ; et al. | 2018-05-24 |
| Dkk1 Antibodies And Methods Of Use App 20180111985 - RICHARDS; William Gleason ; et al. | 2018-04-26 |
| DKK1 antibodies and methods of use Grant 9,879,072 - Richards , et al. January 30, 2 | 2018-01-30 |
| Human CGRP receptor binding proteins Grant 9,862,771 - Boone , et al. January 9, 2 | 2018-01-09 |
| Epitopes Grant 9,353,174 - Paszty , et al. May 31, 2 | 2016-05-31 |
| Human Cgrp Receptor Binding Proteins App 20150376286 - BOONE; Thomas C. ; et al. | 2015-12-31 |
| Antibodies that Bind Myostatin, Compositions and Methods App 20150322144 - Han; Huiquan ; et al. | 2015-11-12 |
| Human CGRP receptor binding proteins Grant 9,102,731 - Boone , et al. August 11, 2 | 2015-08-11 |
| Antibodies that bind myostatin, compositions and methods Grant 8,999,343 - Han , et al. April 7, 2 | 2015-04-07 |
| Epitopes App 20140248666 - Paszty; Christopher J. ; et al. | 2014-09-04 |
| Epitopes Grant 8,715,663 - Paszty , et al. May 6, 2 | 2014-05-06 |
| Antibodies That Bind Myostatin, Compositions And Methods App 20130209489 - Han; Huiquan ; et al. | 2013-08-15 |
| Dkk1 Antibodies And Methods Of Use App 20130209475 - Richards; William Gleason ; et al. | 2013-08-15 |
| Human CGRP Receptor Binding Proteins App 20130071410 - Boone; Thomas C. ; et al. | 2013-03-21 |
| Treatment Methods Using Dkk-1 Antibodies App 20120087912 - Li; Ji ; et al. | 2012-04-12 |
| Treatment methods using Dkk-1 antibodies Grant 8,101,184 - Li , et al. January 24, 2 | 2012-01-24 |
| Sclerostin epitopes Grant 8,003,108 - Lu , et al. August 23, 2 | 2011-08-23 |
| Method for generating F(ab')2 antibody fragments Grant 7,794,970 - Hui , et al. September 14, 2 | 2010-09-14 |
| Human CGRP Receptor Binding Proteins App 20100172895 - Boone; Thomas C. ; et al. | 2010-07-08 |
| Antibodies to Dkk-1 Grant 7,709,611 - Li , et al. May 4, 2 | 2010-05-04 |
| Treatment Methods Using Dkk-1 Antibodies App 20100040619 - LI; Ji ; et al. | 2010-02-18 |
| Binding Agents App 20090304713 - Paszty; Christoper ; et al. | 2009-12-10 |
| Sclerostin-binding antibody Grant 7,592,429 - Paszty , et al. September 22, 2 | 2009-09-22 |
| Method for generating F(ab')2 antibody fragments App 20070154471 - Hui; John O. ; et al. | 2007-07-05 |
| Binding agents App 20070110747 - Paszty; Christopher ; et al. | 2007-05-17 |
| Epitopes App 20070072797 - Robinson; Martyn Kim ; et al. | 2007-03-29 |
| Antibodies to Dkk-1 App 20060127393 - Li; Ji ; et al. | 2006-06-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 